Evotec stock holds near 52-week low as new T-cell alliance meets weak earnings
Published on 09/04/2026 at 08:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Evotec (ISIN DE0005664809) stock is trading close to its 52-week low, with shares at 3.25 EUR on Xetra as of September 4, 2026, even after the company announced a new T-cell research alliance targeting solid tumors according to an article on ad-hoc-news.de.
New T-cell alliance with limited near-term cash impact
Evotec, the Hamburg-based drug discovery group, has entered a collaboration with biotech partner Plectonic Biotech to develop a novel T-cell engager approach for solid tumors, pairing Evotec's BiTco platform with Plectonic's LOGIBODY technology as reported by ad-hoc-news.de.
According to the same report, the Plectonic agreement is the third partnership announced within weeks, following collaborations with Odyssey Therapeutics in autoimmune and inflammatory diseases and a preclinical development mandate from Niagen Bioscience for its NB4168 candidate, highlighting that Evotec's platforms remain attractive to biotech partners despite a challenging share price.
Second-quarter figures show a sharp downturn
Fundamentals remain the key concern for investors. Evotec's latest quarterly figures for the three months to June 30, 2026 (second quarter 2026) show revenue of 143.5 million EUR for the April to June period, with first-half 2026 sales at about 300.1 million EUR, representing a 19.2 percent decline year on year according to ad-hoc-news.de.
A detailed market overview from finanzen.ch confirms that in the quarter ended June 30, 2026, Evotec generated 143.48 million EUR of revenue, down 16.21 percent compared with 171.24 million EUR in the prior-year quarter, while loss per share widened to -0.26 EUR from -0.24 EUR a year earlier.
In addition, adjusted EBITDA swung to a loss of 42.7 million EUR in the first half of 2026 according to the ad-hoc-news.de analysis, underscoring that profitability pressures have intensified even as the company continues to sign new collaborations.
Guidance points to a full-year operating loss
The same ad-hoc-news.de article notes that Evotec's management has reaffirmed significantly reduced full-year guidance issued in July 2026, continuing to project an operating loss of up to 105 million EUR for fiscal year 2026, signaling that the current year is expected to remain loss-making despite the pipeline of partnerships.
Analyst sentiment has weakened in response. According to the ad-hoc-news.de report, one financial portal cut its average price target for Evotec stock to 4.60 EUR from 5.67 EUR in late August 2026, lowering expectations by more than 1.00 EUR and reflecting a more cautious view of the company’s ability to translate its platform deals into earnings.
More data and background on Evotec
For additional regulatory filings, historical performance and long-term charts of Evotec, investors can consult the broader company topic pages and official disclosures.
Stock near MDAX and TecDAX low despite bounce
Market data compiled by finanzen.ch shows that on September 3, 2026, Evotec shares gained 0.5 percent around midday to 3.32 EUR on Xetra, after opening the session at 3.31 EUR and reaching an intraday high of 3.37 EUR, with about 136,747 shares traded, placing the stock among the stronger names in the MDAX at that point.
The same finanzen.ch overview states that Evotec, a TecDAX constituent, hit its lowest level in 52 weeks at 3.12 EUR on September 2, 2026, while the 52-week high of 7.30 EUR was recorded on October 27, 2025, meaning the current price is more than 50 percent below the peak and within about 6.2 percent of the recent low.
According to the ad-hoc-news.de article, Evotec shares now trade at 3.25 EUR, only 3.6 percent above a 52-week low of 3.14 EUR set on September 2, 2026, and roughly 57 percent below a 52-week high of 7.75 EUR reached on November 5, 2025, highlighting how sharply valuation has compressed over the past year.
Business model: discovery platforms and milestone potential
Evotec's business model centers on deploying its discovery and development platforms, such as the BiTco technology, to secure collaborations that can generate upfront payments, research funding, milestones and potential royalties over time according to the ad-hoc-news.de analysis.
The recent sequence of deals with Plectonic, Odyssey Therapeutics and Niagen Bioscience illustrates that the company is actively leveraging its platforms across oncology, autoimmune and inflammatory indications, although both the ad-hoc-news.de report and the finanzen.ch earnings summary emphasize that near-term financial benefits remain limited while losses and revenue declines weigh on results.
Evotec stock price level as of early September 2026
For retail investors, the key takeaway is that Evotec stock is currently priced near its technical floor, at 3.25 EUR per share on Xetra as of September 4, 2026 according to ad-hoc-news.de, only a few percent above the recent 52-week low in a TecDAX and MDAX environment that has seen more stable performance from other constituents.
Evotec at a glance
- Company: Evotec SE
- ISIN: DE0005664809
- WKN: 566480
- Ticker: EVO
- Trading venue: Xetra (Germany)
- Price (as of September 4, 2026): 3.25 EUR
- Market capitalization: 75,200,000 USD (as of September 3, 2026, based on Evotec SE American listing data compiled by StockTitan)
- Sector / Industry: Health Care / Biotechnology
- Index membership: TecDAX, MDAX
